SCHEMBL4884795

SCHEMBL4884795

CCOC(=O)c1cccc(NC(=O)c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.61
GAA P10253 5/20 0.61
LMNA P02545 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HTT P42858 3/20 0.61
MAPK1 P28482 2/20 0.61
MC4R P32245 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
CLK1 P49759 1/20 0.61
GSK3A P49840 1/20 0.61
GSK3B P49841 1/20 0.61
HPGD P15428 2/20 0.59
MAPK14 Q16539 1/20 0.57
TP53 P04637 2/20 0.57
BTK Q06187 4/20 0.56
POLB P06746 1/20 0.56
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
AHR P35869 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4891765 0.81 MAPT (0.63) MAPTGAALMNASMN1; SMN2HTT
SCHEMBL4888741 0.80 MAPT (0.67) MAPTGAALMNASMN1; SMN2HTT
SCHEMBL4890194 0.77 MAPT (0.71) MAPTGAALMNASMN1; SMN2HTT
SCHEMBL4882893 0.77 MAPT (0.57) MAPTGAALMNASMN1; SMN2HTT
SCHEMBL2346099 0.77 MAPK14 (0.60) MAPTGAALMNASMN1; SMN2MAPK1
SCHEMBL24193422 0.77 GAA (0.59) MAPTGAALMNASMN1; SMN2HTT
SCHEMBL4884655 0.77 STAT6 (0.54) MAPTHTTMAPK1MAPK14TP53
SCHEMBL4888073 0.76 MAPK1 (0.66) MAPTGAALMNASMN1; SMN2HTT
SCHEMBL4891734 0.76 MAPK1 (0.60) MAPTLMNAHTTMAPK1ALDH1A1
SCHEMBL2351047 0.75 MAPT (0.65) MAPTGAALMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPT 2064/4885GAA 1084/4885LMNA 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.